why choose us

First received: December 15, 2022

Clinical Trial: Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Parkinson's Disease and Parkinsonism

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Open-label Study to Validate Treatment-induced Biomarkers Following Sargramostim Treatment in Parkinson's Disease

Brief Summary: Investigators will evaluate the safety of a 48 week regimen of Leukine administered as a weight-based dose at 3 ug/kg/ day for 5 days followed by a 2-day holiday.This 48 week long study will extend the prior biomarker evaluations observed in a previous study.Clinical signs and symptoms will be measured by personal well-being, physical, and neurological examinations (UPDRS Parts I, II, III, and IV assessments) and blood tests (CBC with differential, total T cell count, and a comprehensive metabolic sera…

Read more